
16. El‐Galaly TC, Pedersen MB, Hutchings M, et al. Utility of interim and
end‐of‐treatment PET/CT in peripheral T‐cell lymphomas: a review
of 124 patients. Am J Hematol. 2015;90:975‐980.
17. d'Amore F, Gaulard P, Trumper L, et al. Peripheral T‐cell lymphomas:
ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow‐up. Ann Oncol. 2015;26(suppl 5):v108‐v115.
18. AbouYabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A
systematic review and meta‐analysis of front‐line anthracycline‐
based chemotherapy regimens for peripheral T‐cell lymphoma.
ISRN Hematol. 2011;2011:623924. https://doi.org/10.5402/2011/
623924
19. Lage LAPC, Cabral TCS, Costa RO, et al. Primary nodal peripheral
T‐cell lymphomas: diagnosis and therapeutic considerations. Rev
Bras Hematol Hemoter. 2015;37:277‐284.
20. Dearden CE, Johnson R, Pettengell R, et al. Guidelines for the
management of mature T‐cell and NK‐cell neoplasms (excluding
cutaneous T‐cell lymphoma). Br J Haematol. 2011;153:451‐485.
21. Karakas T, Bergmann L, Stutte HJ, et al. Peripheral T‐cell lymphomas
respond well to vincristine, adriamycin, cyclophosphamide, predni-
sone and etoposide (VACPE) and have a similar outcome as high‐
grade B‐cell lymphomas. Leuk Lymphoma. 1996;24(1‐2):121‐129.
22. Wulf GG, Altmann B, Altmann B, et al. Alemtuzumab plus CHOP
versus CHOP in elderly patients with peripheral T‐cell lymphoma:
the DSHNHL2006‐1B/ACT‐2 trial. Leukemia. 2021;35(1):143‐155.
https://doi.org/10.1038/s41375‐020‐0838‐5
23. Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with
chemotherapy for CD30‐positive peripheral T‐cell lymphoma
(ECHELON‐2): a global, double‐blind, randomised, phase 3 trial.
Lancet. 2019;393(10168):229‐240. https://doi.org/10.1016/S0140‐
6736(18)32984‐2
24. Bachy E, Camus V, Thieblemont C, et al. Final analysis of the Ro‐
CHOP Phase III (conducted by LYSA): romidepsin plus CHOP in
patients with peripheral T‐cell lymphoma. 62nd American Society of
Hematology (ASH) Annual Meeting and Exposition; 2020.
25. https://www.nccn.org/professionals/physician_gls/pdf/t‐cell_blocks.
pdf. Accessed 17 Feb 2021
26. Corradini P, Tarella C, Zallio F, et al. Long‐term follow‐up of patients
with peripheral T‐cell lymphomas treated up‐front with high‐dose
chemotherapy followed by autologous stem cell transplantation.
Leukemia. 2006;20:1533‐1538.
27. Kyriakou C, Canals C, Goldstone A, et al. High‐dose therapy and
autologous stem‐cell transplantation in angioimmunoblastic lym-
phoma: complete remission at transplantation is the major deter-
minant of outcome lymphoma working party of the European Group
for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(2):
218‐224.
28. Rodriguez J, Conde E, Gutierrez A, et al. The adjusted International
Prognostic Index and β‐2‐microglobulin predict the outcome after
autologous stem cell transplantation in relapsing/refractory pe-
ripheral T‐cell lymphoma. Haematologica. 2007;92:1067‐1074.
29. Stiff PJ, Unger JM, Cook JR, et al. Autologous transplantation as
consolidation for aggressive non‐Hodgkin's lymphoma. N Engl J Med.
2013;369:1681‐1690.
30. Mounier N, Gisselbrecht C, Brière J, et al. Prognostic factors in pa-
tients with aggressive non‐Hodgkin's lymphoma treated by front‐
line autotransplantation after complete remission: a cohort study
by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol.
2004;22:2826‐2834.
31. Mounier N, Gisselbrecht C, Brière J, et al. All aggressive lymphoma
subtypes do not share similar outcome after front‐line auto-
transplantation: a matched‐control analysis by the Groupe d'Etude
des Lymphomes de l'Adulte (GELA). Ann Oncol. 2004;15:1790‐1797.
32. d'Amore F, Relander T, Lauritzsen GF, et al. Up‐front autologous
stem‐cell transplantation in peripheral T‐cell lymphoma: NLG‐T‐01.
J Clin Oncol. 2012;30:3093‐3099.
33. Reimer P, Schertlin T, Rüdiger T, et al. Myeloablative radio-
chemotherapy followed by autologous peripheral blood stem cell
transplantation as first‐line therapy in peripheral T‐cell lymphomas:
first results of a prospective multicenter study. Hematol J.
2004;5(4):304‐311. https://doi.org/10.1038/sj.thj.6200359
34. Ellin F, Landström J, Jerkeman M, Relander T. Real‐world data on
prognostic factors and treatment in peripheral T‐cell lymphomas: a
study from the Swedish Lymphoma Registry. Blood. 2014;
124(10):1570‐1577.
35. Fossard G, Broussais F, Coelho I, et al. Role of up‐front autologous
stem‐cell transplantation in peripheral T‐cell lymphoma for patients
in response after induction: an analysis of patients from LYSA cen-
ters. Ann Oncol. 2018;29(3):715‐723. https://doi.org/10.1093/
annonc/mdx787
36. Park SI, Horwitz SM, Foss FM, et al. The role of autologous stem cell
transplantation in patients with nodal peripheral T‐cell lymphomas
in first complete remission: report from COMPLETE, a prospective,
multicenter cohort study. Cancer. 2019;125(9):1507‐1517. https://
doi.org/10.1002/cncr.31861
37. Schmitz N, Truemper LH, Bouabdallah K, et al. A randomized phase 3
trial of auto vs. allo transplantation as part of first‐line therapy in
poor‐risk peripheral T‐NHL. Blood. 2020. https://doi.org/10.1182/
blood.2020008825
38. Rashidi A, Cashen AF. Outcomes of allogeneic stem cell trans-
plantation in hepatosplenic T‐cell lymphoma. Blood Cancer J.
2015;5(6):e318. https://doi.org/10.1038/bcj.2015.43
39. Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with
peripheral T‐cell lymphoma after first relapse or progression:
spectrum of disease and rare long‐term survivors. J Clin
Oncol. 2013;31(16):1970‐1976. https://doi.org/10.1200/JCO.2012.
44.7524
40. Dreyling M, Thieblemont C, Gallamini A, et al. ESMO Consensus
conferences: guidelines on malignant lymphoma. Part 2: marginal
zone lymphoma, mantle cell lymphoma, peripheral T‐cell lymphoma.
Ann Oncol. 2013;24:857‐877.
41. Jerkeman M, Leppä S, Kvaløy S, Holte H. ICE (ifosfamide, carbo-
platin, etoposide) as second‐line chemotherapy in relapsed or pri-
mary progressive aggressive lymphoma—the Nordic Lymphoma
Group experience. Eur J Haematol. 2004;73:179‐182.
42. Philip T, Chauvin F, Armitage J, et al. Parma international protocol:
pilot study of DHAP followed by involved‐field radiotherapy and
BEAC with autologous bone marrow transplantation. Blood.
1991;77:1587‐1592.
43. Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S,
Moskowitz CH Ifosfamide, carboplatin, etoposide (ICE)‐based
second‐line chemotherapy for the management of relapsed and re-
fractory aggressive non‐Hodgkin's lymphoma. Ann Oncol.
2003;14(suppl 1):i5‐i10.
44. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP—an effective
chemotherapy regimen in refractory and relapsing lymphoma: a 4‐
year follow‐up study. J Clin Oncol. 1994;12:1169‐1176.
45. Skamene T, Crump M, Savage KJ, et al. Salvage chemotherapy and
autologous stem cell transplantation for peripheral T‐cell lymphoma:
a subset analysis of the Canadian Cancer Trials Group LY.12 ran-
domized phase 3 study. Leuk Lymphoma. 2017;58(10):2319‐2327.
https://doi.org/10.1080/10428194.2017.1312379
46. Kharfan‐Dabaja MA, Kumar A, Ayala E, et al. Clinical practice rec-
ommendations on indication and timing of hematopoietic cell
transplantation in mature T cell and NK/T cell lymphomas: an in-
ternational collaborative effort on behalf of the guidelines commit-
tee of the American Society for Blood and Marrow Transplantation.
Biol Blood Marrow Transplant. 2017;23(11):1826‐1838. https://doi.
org/10.1016/j.bbmt.2017.07.027
47. Loirat M, Chevallier, P, Leux C, et al. Upfront allogeneic stem‐cell
transplantation for patients with nonlocalized untreated peripheral
LUMINARI AND SKRYPETS
-
59